KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer. - Wikidata - awgldk - TriplyDB

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

http://www.wikidata.org/entity/Q41952724

about

Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis.Meta-analysis comparing the efficacy of nedaplatin-based regimens between squamous cell and non-squamous cell lung cancers.Am I ready for CRISPR? A user's guide to genetic screens.KEAP1 Editing Using CRISPR/Cas9 for Therapeutic NRF2 Activation in Primary Human T Lymphocytes.KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target.NRF2 Addiction in Cancer Cells.Application of CRISPR-Cas9 Based Genome-Wide Screening Approaches to Study Cellular Signalling Mechanisms.Epigenetic versus Genetic Deregulation of the KEAP1/NRF2 Axis in Solid Tumors: Focus on Methylation and Noncoding RNAs.[Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features].YES1 amplification is a mechanism of acquired resistance to EGFR inhibitors identified by transposon mutagenesis and clinical genomics.Metformin reverses the resistance mechanism of lung adenocarcinoma cells that knocks down the Nrf2 gene

P2860

Q33862425-756E0122-8606-4A8E-8AE8-98B8B07A9977 Q41992348-5C790F94-A4ED-442C-B8C8-B4AB0AD9FC83 Q42365337-E2F9A186-5183-4993-8A49-E88A14C898FB Q47281660-DDDC11BA-2A1A-4CC0-A010-1D6E02CA4771 Q48204957-E4CF35CE-AF07-4D9D-9A53-21B320384A1B Q49887897-1138F4B5-95ED-4ACE-851C-5194E6D740CC Q49945078-34C91A5F-8468-44AA-8C62-604D05BCF1E4 Q52347926-CA4BC3DF-34A2-48E7-8D6A-6D84FF42A5F9 Q53696229-4E139A67-E68A-4ED2-9B4E-03D0569EA6D7 Q54119052-A0BD1580-413C-4D6A-912C-89BB2FCC3C1E Q55634316-A5239955-4C19-4574-95E7-F0C125ECAB7C Q58573280-CAB5AC84-A69E-4CD8-9A3D-4548FD2D15DF

P2860

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

http://www.wikidata.org/entity/Q41952724

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

@en

type

label

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

@en

prefLabel

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

@en

P1433

Q41952724-4D6A47B4-A69B-487B-8CF7-34746118D213

P1476

Q41952724-A94E1391-A00A-483E-BFB6-AE30A46D595F

P2093

Q41952724-0C738C83-C353-4825-8B16-9A0780347A57

Q41952724-15E992A2-4D4B-487A-8438-064A7872C867

Q41952724-16096010-28E8-4648-A594-05139E302220

Q41952724-1A8046DD-6699-4ECF-9135-D53A2151EE3E

Q41952724-2ACF23BD-26BD-492B-A0A5-1C1E0F748ACD

Q41952724-2FEBAB77-9EBE-41C2-AD41-783836CBB51B

Q41952724-306E11AD-4847-44C3-9458-315FA89279EB

Q41952724-3F009523-DAE9-4456-B705-ECB31F2871BB

Q41952724-432FCFA4-107F-449A-8E2A-917731FC1C08

Q41952724-47B4790B-B4E3-4279-B986-E037EB8A64D0

P2860

Q41952724-08D410AB-CF65-4105-A51B-2E147CDD7505

Q41952724-09848114-8021-496E-9C61-0AE23F68312B

Q41952724-0C36F8EC-56EF-40C5-AE9C-8AB134411386

Q41952724-19E77DED-D83E-45D2-A83C-604EFE65B58E

Q41952724-1BA50AC9-0386-4DC7-B104-F8F0FEC52895

Q41952724-1D79B177-D0B3-4B1C-A6A5-C3827ABF80C1

Q41952724-1E08EF95-4669-40BC-9863-6E7EBD028082

Q41952724-2201C584-98DD-4F05-9645-4A4DD5872C9F

Q41952724-22EF9898-86FE-4A61-9059-967F192D2E9B

Q41952724-2A6D722A-F876-4B07-8533-54327D619298

P31

Q41952724-953FD276-CF0B-4052-892D-C7B4F1A44D1C

P356

Q41952724-9F79C441-089B-473F-8F24-77EDADC96C87

P407

Q41952724-274CE804-3D28-4566-9BF7-7DEC680D14BD

P478

Q41952724-0F39EADC-5C2F-4192-AD5F-774E4145D21A

P50

Q41952724-81BBAA3C-3736-400A-845C-B11D061B180B

P577

Q41952724-45115DA6-2178-4D64-95C9-332620E643E1

P698

Q41952724-AE284C23-23A4-4FC5-A9D8-0089DCD5799A

P932

Q41952724-6D7D7201-0513-4CDC-B801-154644B5B378

P356

P1433

P1476

KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer.

@en

P2093

Alice T Shaw

http://www.w3.org/2001/XMLSchema#string

Amanda J Redig

http://www.w3.org/2001/XMLSchema#string

Andrew J Aguirre

http://www.w3.org/2001/XMLSchema#string

Belinda Wang

http://www.w3.org/2001/XMLSchema#string

David A Ruddy

http://www.w3.org/2001/XMLSchema#string

Diana M Munoz

http://www.w3.org/2001/XMLSchema#string

Elsa B Krall

http://www.w3.org/2001/XMLSchema#string

Frank Stegmeier

http://www.w3.org/2001/XMLSchema#string

Jeffrey A Engelman

http://www.w3.org/2001/XMLSchema#string

John G Doench

http://www.w3.org/2001/XMLSchema#string

P2860

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2

Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

Somatic mutations affect key pathways in lung adenocarcinoma

Cancer related mutations in NRF2 impair its recognition by Keap1-Cul3 E3 ligase and promote malignancy

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer.

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition.

P31

scholarly article

P356

10.7554/ELIFE.18970

http://www.w3.org/2001/XMLSchema#string

P407

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28145866

http://www.w3.org/2001/XMLSchema#string

P932

5305212

http://www.w3.org/2001/XMLSchema#string